Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to mRNA COVID-19 Vaccines After Prior Therapy
NCT04952402Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04952402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952402.